Future of Bio-Rad Laboratories | Quantumrun

Future of Bio-Rad Laboratories

Bio-Rad Laboratories, Inc., was founded in 1953 in Berkeley, Calif., but is currently based in Hercules, Calif. The company develops, creates and markets products and solutions for life science research and clinical diagnostics. It was initially focused in creating and producing specialty chemicals used in biochemical, pharmaceutical and other life science research applications. Currently, Bio-Rad creates products and systems that are used to separate complex chemical and biological materials, and used to identify, analyze and purify their components. It provides these products to life science research, healthcare and other markets. Bio-Rad has direct distribution channels in more than 35 countries around the world.

Home Country: 
United States
Industry: 
Life Science
Industry vulnerability to disruption: 

<p>Belonging to the pharmaceuticals sector means this company will be affected directly and indirectly by a number of disruptive opportunities and challenges over the coming decades. While described in detail within Quantumrun’s special reports, these disruptive trends can be summarized along the following broad points:</p>

<p>*First off, the late 2020s will see the Silent and Boomer generations enter deep into their senior years. Representing nearly 30-40 per cent of the global population, this combined demographic will represent a significant strain on the health systems of developed nations.<br />
*However, as an engaged and wealthy voting block, this demographic will actively vote for increased public spending on health services to support them in their greying years.<br />
*The economic strain of this massive senior citizen demographic will encourage developed nations to fast-track the testing and approval process for new drugs that may improve the overall physical and mental health of seniors, so that they remain well enough to lead independent lives outside the care of hospitals and nursing homes.<br />
*By the early 2030s, a range of treatments will emerge to stunt and later reverse the effects of aging. These treatments will be provided annually and over time will become affordable to the masses, resulting in longer average human lifespans and a new windfall for the pharmaceutical industry.<br />
*By 2050, the world population will rise above nine billion, over 80 percent of whom will live in cities. The high numbers and density of the future human population will result in more regular pandemic outbreaks that spread faster and are harder to cure.<br />
*The eventual widespread adoption of artificial intelligence (AI) and quantum computing within the pharmaceutical industry will lead to new, AI-assisted discoveries of drugs and treatments to cure a range of medical conditions. These AI pharmaceutical researchers will also result in new drugs and treatments being discovered at a far faster rate than is currently possible.</p>

Total patents held: 
560
Number of patents field last year: 
7
Ranking List: 
243
Ranking List: 
2017 Quantumrun Global 1000
165
Ranking List: 
2017 Quantumrun US 500
23
Ranking List: 
2017 Quantumrun Silicon Valley 100
Market Revenue Country: 
Market country 
United States
Revenue from country 
0.37
Market country 
Europe
Revenue from country 
0.36
Prod/Serv name revenue: 
Prod/Serv name: 
Life science
Prod/Serv revenue: 
730700000
Prod/Serv name: 
Clinical diagnostics
Prod/Serv revenue: 
1320000000
Founded: 
1952
Company Name: 
Bio-Rad Laboratories
Revenue: 
2068172000
3y average revenue: 
2087552333
Operating expenses: 
1084893000
3y average expenses: 
1022796000
Company profile data note: 
All company data collected from its 2016 annual report and other public sources. The accuracy of this data and the conclusions derived from them depend on this publicly accessible data. If a data point listed above is discovered to be inaccurate, Quantumrun will make the necessary corrections to this live page.
Global employee count: 
8250
Domestic employee count: 
3300
Number of domestic locations: 
3
Funds in reserve: 
456264000
Investment into R&D: 
205864000
create term: 
#243 | 2017 Quantumrun Global 1000
#165 | 2017 Quantumrun US 500
#23 | 2017 Quantumrun Silicon Valley 100

Bio-Rad Laboratories, Inc., was founded in 1953 in Berkeley, Calif., but is currently based in Hercules, Calif. The company develops, creates and markets products and solutions for life science research and clinical diagnostics. It was initially focused in creating and producing specialty chemicals used in biochemical, pharmaceutical and other life science research applications. Currently, Bio-Rad creates products and systems that are used to separate complex chemical and biological materials, and used to identify, analyze and purify their components. It provides these products to life science research, healthcare and other markets. Bio-Rad has direct distribution channels in more than 35 countries around the world.

Home country:
United States
Sector:
Pharmaceuticals
Industry:
Life Science
Founded:
1952
Global employee count:
8,250
Domestic employee count:
3,300

Financial Health

Revenue
$2,068,172,000 USD
3y average revenue
$2,087,552,333 USD
Operating expenses
$1,084,893,000 USD
3y average expenses
$1,022,796,000 USD
Funds in reserve
$456,264,000 USD
#1 Market country
United States
% of revenue from country #1
0.37%
#2 Market country
Europe
% of revenue from country #2
0.36%

Asset Performance

#1 Product/Service/Dept. name
Life science
#1 Product/Service revenue
$730,700,000 USD
#2 Product/Service/Dept. name
Clinical diagnostics
#2 Product/Service revenue
$1,320,000,000 USD

Innovation assets and Pipeline

Investment into R&D
$205,864,000 USD
Total patents held
560
Number of patents field last year
7
All company data collected from its 2016 annual report and other public sources. The accuracy of this data and the conclusions derived from them depend on this publicly accessible data. If a data point listed above is discovered to be inaccurate, Quantumrun will make the necessary corrections to this live page.

Disruption Vulnerability

Belonging to the pharmaceuticals sector means this company will be affected directly and indirectly by a number of disruptive opportunities and challenges over the coming decades. While described in detail within Quantumrun’s special reports, these disruptive trends can be summarized along the following broad points:

*First off, the late 2020s will see the Silent and Boomer generations enter deep into their senior years. Representing nearly 30-40 per cent of the global population, this combined demographic will represent a significant strain on the health systems of developed nations.

*However, as an engaged and wealthy voting block, this demographic will actively vote for increased public spending on health services to support them in their greying years.

*The economic strain of this massive senior citizen demographic will encourage developed nations to fast-track the testing and approval process for new drugs that may improve the overall physical and mental health of seniors, so that they remain well enough to lead independent lives outside the care of hospitals and nursing homes.

*By the early 2030s, a range of treatments will emerge to stunt and later reverse the effects of aging. These treatments will be provided annually and over time will become affordable to the masses, resulting in longer average human lifespans and a new windfall for the pharmaceutical industry.

*By 2050, the world population will rise above nine billion, over 80 percent of whom will live in cities. The high numbers and density of the future human population will result in more regular pandemic outbreaks that spread faster and are harder to cure.

*The eventual widespread adoption of artificial intelligence (AI) and quantum computing within the pharmaceutical industry will lead to new, AI-assisted discoveries of drugs and treatments to cure a range of medical conditions. These AI pharmaceutical researchers will also result in new drugs and treatments being discovered at a far faster rate than is currently possible.